Today, Cynata's CEO and MD, Dr Kilian Kelly and CBO Dr Mathias Kroll, provided an update to investors, following the release of the ASX Quarterly Activity Report for the December 2024 quarter.

Following the release of our ASX Quarterly Activity Report for the period ending 31 December 2024, leading small business journalist Tim Boreham covered our highlights and milestones.

Read his article here: https://tinyurl.com/yda8z87h

A comparison of Cynata’s innovative Cymerus™ platform to conventional MSCs has been highlighted in a study published in npj Regenerative Medicine, a prestigious peer-reviewed journal by Nature Portfolio.

The study, led by Monash University researchers found significant advantages of Cynata’s iPSC-derived MSCs in consistency, regenerative potential, and immunomodulatory effects and key differences between MSCs from various sources, with Cynata’s platform showcasing unique benefits for therapeutic applications.

Read the news coverage here: https://tinyurl.com/y8fpntk4

Today, Cynata's CEO and MD, Dr Kilian Kelly and CBO Dr Mathias Kroll, provided an update to investors, following the release of the Phase 1 diabetic foot ulcer clinical trial results.

Euroz Hartleys analyst Seth Lizee has initiated research coverage on Cynata. Read the report here.